Expanded Prostate Cancer Screening Trial to Reach More Black Men

A significant expansion of a UK-based prostate cancer screening trial will invite tens of thousands of additional black men, aged between 45 and 74, to undergo testing. This initiative aims to refine diagnostic methods for the disease. The government’s announcement has been hailed by campaigners and charities as a "truly historic moment."

This development occurs alongside official support for the UK National Screening Committee’s recent stance that routine testing should not be offered to the general male population. The committee argues that for the majority of cases, the risks associated with PSA (prostate-specific antigen) blood test screening outweigh the potential benefits. Exceptions are made only for a small number of men who possess a dangerous genetic variant and have a family history of cancer.

While individuals are encouraged to consult their doctors regarding the potential utility of a PSA test, and advised not to disregard symptoms like urinary difficulties, the practice of screening asymptomatic healthy men remains controversial. Although early detection can save lives, it often leads to treatments that may result in incontinence or erectile dysfunction. Furthermore, because many prostate tumors are slow-growing and may never become life-threatening, widespread screening is currently not recommended.

Prostate cancer remains the most prevalent cancer among men in the UK, with approximately 64,000 diagnoses and 12,000 deaths annually. The lifetime risk is one in eight for the general male population, but this risk doubles to one in four for black men.

To address this disparity, the government has committed £18 million to the Transform trial. This research seeks to determine if combining PSA tests with additional procedures, such as genetic screenings and rapid MRI scans, can enhance screening precision. All black men within the target age group who have not recently undergone a PSA test will be invited to join the study. Officials state that the trial is designed to establish a more effective future screening framework.

James Murray, the Health Secretary, emphasized the significance of the move: "This is a major step forward in how we tackle prostate cancer - focusing on those most at risk, improving the treatments available, and backing the research we need to close the evidence gaps and save lives."

The trial began inviting participants earlier this year. Prostate Cancer UK expressed its delight at the government’s decision, noting that it will enable the charity to provide more black men with reliable and clear information.

Source: BBC News Generated at: 2026-06-02 14:52:06 UTC